Fenticlor
CAS 97-24-5
Fenticlor (CAS 97-24-5) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 31 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 28881.54298245614 nM | 108 | - |
| - | GI50 | 11974.132033898306 nM | 59 | - |
| - | IC50 | 9639.990434782609 nM | 22 | - |
| - | AC50 | 7237.839999999999 nM | 5 | - |
| - | MIC | 50 ug.mL-1 | 3 | - |
| - | EC50 | 18700 nM | 1 | - |
| Uracil-DNA glycosylase Enzyme |
IC50 | 4.41 | - | Vaccinia virus (strain Western Reserve) |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Fenticlor used for in pharmaceutical contexts?
Fenticlor (CAS 97-24-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Fenticlor?
Fenticlor has 31 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abnormal sensation in eye, Arthropathy, Back pain, Blindness, Blindness transient. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Fenticlor also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for 2,2'-Thiobis(4-Chlorophenol) with EU status "prohibited".
What clinical phase is Fenticlor in?
Fenticlor is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Fenticlor?
Fenticlor has 7 bioactivity rows in this page query. Rendered target entries include Uracil-DNA glycosylase.